GlassScriptPhysician profile
James P Wigand
NPI 1831198019
$9,141.03
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,937 · 2020: $204.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $8,324.52 | 2019-2020 | |
| Amgen INC. | $265.68 | 2019 | |
| Lilly USA, LLC | $239.87 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.49 | 2019-2020 | |
| Novo Nordisk INC | $58.36 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $31.59 | 2019 | |
| Insulet Corporation | $29.98 | 2019 | |
| Radius Health, INC. | $18.92 | 2019 | |
| Xeris Pharmaceuticals, INC. | $12.93 | 2020 | |
| Merck Sharp & Dohme LLC | $12.24 | 2019 | |
| Lifescan, INC. | $11.45 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wigand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.